The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease

Karuppagounder, Senthilkumar S., Brahmachari, Saurav, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M., Ko, Han Seok·2014·Scientific Reports
DOI 10.1038/srep04874

Cited by (268)

Items 201–268 of 268

  1. Nilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year
    Woo‐Jin Lee, Jangsup Moon, Yoonhyuk Jang, Yong-Woo Shin, Hyoshin Son, Seoyi Shin, Daejong Jeon, Dohyun Han, Soon‐Tae Lee, Kyung‐Il Park et al. · 2024 · Scientific Reports
  2. Cerebrolysin peptides as mood stabilizers
    Ivan Yu. Torshin, Ольга Алексеевна Громова, Victor Gavrilovich Zgoda, Olga V. Tikhonova, Svetlana I. Malyavskaya · 2019 · S S Korsakov Journal of Neurology and Psychiatry
  3. Drug Repurposing for Hematological Malignancies
    Antony Anista Michael, Pavithra Balakrishnan, Thirunavukkarasu Velusamy · 2023 · Springer eBooks
  4. Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease
    Priya P. Shejul, Gaurav Doshi · 2024 · Central Nervous System Agents in Medicinal Chemistry
  5. Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease
    Peter A. LeWitt · 2020 · JAMA Neurology
  6. Comprehensive Bioinformatics Analysis Reveals Molecular Signatures and Potential Caloric Restriction Mimetics with Neuroprotective Effects: Validation in an In Vitro Stroke Model
    Navami Krishna, Neelakandan Annamalai Ramalakshmi, Rajanikant Golgodu Krishnamurthy · 2025 · Journal of Molecular Neuroscience
  7. Mitochondrial Dysfunction in the Pathogenesis of Parkinson Disease: Current Concepts and Potential Therapeutic Strategies
    Н. Г. Жукова, Yu. V. Kolobovnikova, Zaynutdinkhuzha F. Sayfitdinkhuzhaev · 2025 · Annals of Clinical and Experimental Neurology
  8. Targeting protein kinases in Parkinson’s disease: the emerging role of phytoconstituents
    Disha Joshi, Mangesh Kulkarni, Pathik Parekh, Shreeraj Shah, Nigel H. Greig, Sheetal Porecha Acharya · 2025 · Nutritional Neuroscience
  9. The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
    Margaux Teil, Philippe Huot · 2026 · Current Opinion in Neurobiology
  10. DYRK1A and Parkinson’s disease, facts and hypotheses
    Laurent Meijer, Mattias F. Lindberg, Gaëlle Hogrel, Bernard Khor · 2026 · Neurobiology of Disease
  11. Drug repurposing for disease-modifying effects in multiple system atrophy
    Seong Ho Jeong, Jin Young Shin, Phil Hyu Lee · 2026 · Translational Neurodegeneration
  12. Synergizing drug repurposing and target identification for neurodegenerative diseases
    Mehar Sahu, Shrutikirti Vashishth, Neha Kukreti, Ashima Gulia, Ashish Russell, Rashmi K. Ambasta, Pravir Kumar · 2024 · Progress in molecular biology and translational science
  13. Neuroprotective Activity of a Non-Covalent Imatinib+TP10 Conjugate in HT-22 Neuronal Cells In Vitro
    Izabela Rusiecka, Iwona Gągało, Ivan Kocić · 2024 · Pharmaceutics
  14. Tyrosine Kinase Inhibitors and Neurodegenerative Disorders
    Syed Jafar Mehdi, Steven W. Barger, Merle G. Paule, Syed F. Ali, Syed Z. Imam · 2016 · Oxidative stress in applied basic research and clinical practice
  15. Nilotinib
    Giuseppe Tridente · 2017 · Elsevier eBooks
  16. Autophagy Mechanisms for Brain Recovery. Keep It Clean, Keep It Alive
    Annalisa Nobili, Livia La Barbera, Roberta Mastrantonio, Claudia Palazzo, Marco Molinari, Marcello D’Amelio, Maria Teresa Viscomi · 2023 · Contemporary clinical neuroscience
  17. Combination Disease‐Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs
    Alexander Shtilbans, Anthony Edward Lang · 2026 · Annals of Neurology
  18. Discovery of conformationally constrained c-Abl inhibitors with potential neuroprotective effects against Parkinson’s disease
    Zichao Yang, Yangcheng Ai, Guowu Wu, Fengqiu Guo, Zilong Yang, Beijun Cheng, Lishun Zhang, Mingxia Li, Jianjun Chen, Tingting Zhang et al. · 2023 · Bioorganic & Medicinal Chemistry
  19. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
    Suneela Sunil Dhaneshwar, Mohammad Aadil Bhat, Anuradha Singh, Supriya Roy · 2024 · BENTHAM SCIENCE PUBLISHERS eBooks
  20. Monitoring Parkinson’s Disease Rehabilitation from Phonation Biomechanics
    Pedro Gómez‐Vilda, Pilar Lirio, Daniel Palacios Alonso, V. Rodellar, N. Polo · 2016 · Biosystems & biorobotics
  21. Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia
    Justine Chan, Paarth Shah, Guillermo Moguel‐Cobos · 2019 · Case Reports in Neurological Medicine
  22. Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
    Steve Pedrini, Mike Morici, Ralph Nigel Martins · 2019 · Wiley eBooks
  23. Advancements in Brain Diseases: Exploring the Complexities and Pursuing Therapeutic Breakthroughs
    Abdullah Al Mutery, Irfan Hussain, Kainaat Mumtaz · 2023 · Preprints.org
  24. Advances in Disease Modifying Therapies for Parkinson's Disease
    Kambiz Hassanzadeh, M. Maral Mouradian · 2025 · Wiley eBooks
  25. Reactive Astrocytes Drive Extracellular Acidification to Mediate α-Synuclein Neurodegeneration
    Jae‐Jin Song, Hyejin Park, YuRee Choi, Taekyung Ryu, Jisu Shin, Seo-Hyun Kim, Albert Park, Justin Wang, Devanik Biswas, Shih-Ching Chou et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  26. Repurposing Clinic-Tested Drugs to Treat Rare Neurogenetic Diseases by Transcriptional Modulation
    Jeremiah Hadwen · 2018 · uO Research (University of Ottawa)
  27. Pick the Company 企業紹介(第76回 2)株式会社TV・ポータル
    和俊 平田, 邦壽 武居 · 2010 · 衛星&ケーブルテレビ
  28. In Vitro α-synuclein aggregation assay for studying induced cellular stress, drug targets and compounds
    Severi Anttila · 2019 · UTUPub (University of Turku)
  29. Neuroprotective Effect of Nilotinib on Cortical Pyramidal Cells, Histological, Morphometric and Biochemical Study
    Ahmed S. Ahmed · 2020 · Annual Research & Review in Biology
  30. Parkinson's disease: Genetic-driven therapeutic approaches
    S. Pablo Sardi, Marco A. S. Baptista · 2020 · Elsevier eBooks
  31. Faculty Opinions recommendation of Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
    Dongsheng Cai · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  32. Faculty Opinions recommendation of Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.
    Dan Lindholm · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  33. Faculty Opinions recommendation of Targeted therapies for parkinson's disease: from genetics to the clinic.
    Joseph J. Jankovic, Arjun Tarakad · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  34. Faculty Opinions recommendation of Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
    Richard J Naftalin · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  35. A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease
    Tanya Simuni, Kalpana Merchant · 2023 · Parkinsonism & Related Disorders
  36. Food as medicine: Curbing type-2 diabetes prevalence through consumption of high amylose starchy foods in Sub-Saharan Africa
    Muyiwa Seyi Adegbaju, Ifeoluwa E Adegbaju, Issah A Memunat, Fatimatou Saccoh, Ademola A Falade, James Richard Lloyd, Olanrewaju B. Morenikeji · 2025 · Advanced Pharmaceutical Bulletin
  37. c-Abl Inhibitors in Parkinson's: Exploring Hypotheses on Alpha-Synuclein Modulation
    Jyutia Nargish, Hirok Jyoti Baishya, Piyong Sola · 2025 · Advanced Pharmaceutical Bulletin
  38. Computational Discovery of the Neuroprotective Potential of Karanjin Against Parkinson's Disease
    Ragavendhar Gopinath, Chetan Ashok, Naveen Kumar Rajasekaran, Mahendran Sekar, Parasuraman Pavadai, Ling Shing Wong, Vetriselvan Subramaniyan, Srikanth Jeyabalan · 2025 · ChemistrySelect
  39. Additional file 3 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Valina Lynn Dawson, Dawson, Ted M. · 2020 · Figshare
  40. Additional file 13 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  41. Additional file 6 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  42. Additional file 7 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  43. Additional file 15 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  44. Additional file 16 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  45. Additional file 11 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  46. Additional file 14 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  47. Additional file 9 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  48. Additional file 1 of Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
    Kevin Peikert, Enrica Federti, Matte, Alessandro, Gabriela Constantin, Enrica Caterina Pietronigro, Paolo Francesco Fabene, Paola Defilippi, Turco, Emilia, Federico Del Gallo, Pucci, Pietro et al. · 2021 · Figshare
  49. Additional file 8 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  50. Additional file 1 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  51. Additional file 10 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  52. Additional file 2 of PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
    Sheila K. Pirooznia, Changqing Yuan, Mohammed Repon Khan, Senthilkumar S. Karuppagounder, Wang, Luan, Xiong, Yulan, Sung Ung Kang, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M. · 2020 · Figshare
  53. Molecular Insights Into Repurposed Drug Interactions With HDAC11 for Advancing Epigenetic Therapeutics in Cancer and Neurodegenerative Diseases
    YUNG G. YANG, Khalida Ahmed Mohammed Ahmed, Khuzin Dinislam, Pratibha Prasad, Akhtar Atiya · 2026 · Journal of Chemistry
  54. Modélisation et recherche de stratégies expérimentales dans l’atrophie multisystématisée
    Paul A. Guerin · 2018
  55. Mitochondrial resilience: a convergent framework for pathogenesis and neuroprotection in Parkinson’s disease
    Óscar Arias-Carrión, Magdalena Guerra‐Crespo, Luis Oskar Soto-Rojas, Yeminia Valle, Emmanuel Ortega‐Robles, Daniel Ortuño‐Sahagún · 2026 · Frontiers in Pharmacology
  56. Hyperbolic graph contrastive learning for drug repositioning over heterogeneous biological networks
    Pengli Lu, Yu Ge, Shengfang Wan, Erjia Peng, Jun Zhang, Zhiwei Yang · 2026 · Computational Biology and Chemistry
  57. Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson’s disease: mechanisms and future directions
    Praveen Kumar Gaur, Prachee Raje Bisht, Sonia Lal Gupta · 2026 · Journal of Biomaterials Science Polymer Edition
  58. Mitophagy in neuronal health and disease: from mechanisms to neurodegeneration
    Bishal Basak, Julia F. Riley, Neha M. Nataraj, Erika L.F. Holzbaur · 2026 · Journal of Clinical Investigation
  59. Nilotinib attenuates NLRP3 inflammasome activation and GSDMD/NINJ1-mediated pyroptosis via modulation of NF-κB signaling and enhancement of BAG3-dependent aggrephagy and ESCRT-III-mediated plasma membrane repair in microglia
    Mehmet Erdem, Şeniz Erdem, Süleyman Caner Karahan · 2026 · Journal of Neuroimmunology
  60. Pharmacological targets for Parkinson’s disease
    Abhishek Kumar Mishra, Dipak Kumar · 2026 · Advances in pharmacology
  61. Neuroprotective therapies in Parkinson's disease
    Hadeer N. Atalah, Mai Barakat, Esraa M Qansuwa · 2026 · Elsevier eBooks
  62. BindingDB Entry 50020333: Development of
    BindingDB · 2024 · UC San Diego
  63. BindingDB Entry 50018480: A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
    BindingDB · 2024 · UC San Diego
  64. BindingDB Entry 50010397: Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.
    BindingDB · 2021 · UC San Diego
  65. BindingDB Entry 50019468: Discovery of conformationally constrained c-Abl inhibitors with potential neuroprotective effects against Parkinson's disease.
    BindingDB · 2024 · UC San Diego
  66. BindingDB Entry 50014717: A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease.
    BindingDB · 2022 · UC San Diego
  67. BindingDB Entry 50019815: Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate α-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice.
    BindingDB · 2024 · UC San Diego
  68. BindingDB Entry 50018076: Discovery of 4-methyl-3-(pyridin-2-ylamino)benzamide derivatives as C-Abl inhibitors with potential neuroprotective effect.
    BindingDB · 2023 · UC San Diego